Vor Ort
Merkzettel Warenkorb
  • Produktbild: The CNS Control of Glucose Metabolism
  • Produktbild: The CNS Control of Glucose Metabolism
Band 31

The CNS Control of Glucose Metabolism

Aus der Reihe Acta Neurochirurgica Supplement

49,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.06.1981

Verlag

Springer Wien

Seitenzahl

160

Maße (L/B/H)

22,9/15,2/1 cm

Gewicht

259 g

Auflage

Softcover reprint of the original 1st ed. 1981

Sprache

Englisch

ISBN

978-3-211-81619-6

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.06.1981

Verlag

Springer Wien

Seitenzahl

160

Maße (L/B/H)

22,9/15,2/1 cm

Gewicht

259 g

Auflage

Softcover reprint of the original 1st ed. 1981

Sprache

Englisch

ISBN

978-3-211-81619-6

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Ein neues Kapitel für Ihre Bücher

Ein neues Kapitel für Ihre Bücher

Schenken Sie Ihren alten Schätzen ein zweites Leben: Einfach Barcode scannen, Versandetikett ausdrucken, Bücher verschicken und Thalia Geschenkkarte erhalten.

Jetzt verkaufen
Jetzt verkaufen

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: The CNS Control of Glucose Metabolism
  • Produktbild: The CNS Control of Glucose Metabolism
  • 1. Introduction.- 2. The Regulation of Glucose Metabolism.- 2.1. Non-Nervous Regulation.- 2.1.1. Intrinsic Cell Mechanisms.- 2.1.2. Hormonal Action.- 2.1.2.1. Insulin.- 2.1.2.2. Glucagon.- 2.1.2.3. Glucocorticoids.- 2.1.2.4. Growth Hormone.- 2.2. Central Nervous Regulation.- 2.2.1. Neural Regulation.- 2.2.1.1. Early Experimental Findings in Animals.- 2.2.1.2. “Neurotraumatic” Diabetes.- 2.2.1.3. Diencephalic Structures and Organization of the Autonomie Nervous System. Results of Stimulation and Ablation Experiments.- 2.2.1.4. Neural Influences on the Liver Cells, on Glycogenolysis and Glycogen Synthesis.- 2.2.1.5. Neural Stimulation of the Adrenal Medulla and the Role of Catecholamines.- 2.2.1.6. Nerve Supply to the Cells of the Islets of Langerhans.- 2.2.1.7. Neural Control of Glucagon Secretion.- 2.2.1.8. Neural Control of Insulin Secretion.- 2.2.2. Neurohumoral Regulation.- 2.2.2.1. The Hypothalamic-Pituitary System.- 2.2.2.2. Glucose-Sensitive Neurones in the Hypothalamus.- 2.2.2.3. Effect of the Location of Diencephalic Lesions on the Clinical and Endocrine Symptoms.- 2.3. Summary.- 3. Methods Employed.- 3.1 Standardization of the Withdrawal of Blood.- 3.2 Standardization of the Loading Tests.- 3.2.1. Intravenous Glucose Load.- 3.2.2. Insulin Hypoglycaemia.- 3.2.3. Arginine “Stress”.- 3.2.4. Somatostatin Load.- 3.3 Chemical Estimation Methods.- 3.3.1. Glucose.- 3.3.2. Free Fatty Acids.- 3.3.3. Human Growth Hormone.- 3.3.4. Insulin.- 3.3.5. Cortisol.- 3.3.6. Glucagon.- 3.3.7. Catecholamines.- 3.4 Pharmacokinetics of Glucose.- 3.5 Statistical Methods.- 4. Results.- 4.1. Survey of Material and Subdivision into Groups.- 4.2. Preliminary Studies.- 4.3. Spontaneous Behaviour.- 4.3.1. Severe Closed Craniocerebral Injury, Acute Subdural Haematoma, Secondary Coma and Midbrain Syndrome.- 4.3.2. Acute Midbrain Syndrome with Extensive Intracranial Haemorrhage.- 4.3.3. Severe Craniocerebral Injury, Acute Hypothalamic Damage.- 4.3.4. Acute Hypothalamic Damage with Transition into a Midbrain Syndrome, Bulbar Damage and Brain Death After Embolization of an A.V. Angioma.- 4.3.5. Hypothalamic Damage After Operation on a Medial Sphenoidal Wing Meningioma.- 4.4. Intravenous “Stress” with Glucose 0.33 g/kg Body Weight.- 4.4.1. Healthy Subjects.- 4.4.2. Diabetics.- 4.4.3. All Intracranial Tumours.- 4.4.3 a. Pre-Operative.- 4.4.3 b. First Post-Operative Day.- 4.4.3 c. Seventh Post-Operative Day.- 4.4.4. Endocrine Inactive Intra- and Suprasellar Pituitary Tumours.- 4.4.4 a. Pre-Operative.- 4.4.4 b. First Post-Operative Day.- 4.4.4 c. Seventh Post-Operative Day.- 4.4.5. Endocrine Active Eosinophilie Adenomas with Pathological HGH Secretion.- 4.4.5 a. Pre-Operative.- 4.4.5 b. First Post-Operative Day.- 4.4.5 c. Seventh Post-Operative Day.- 4.4.6. Patients with Complete Anterior Pituitary Failure.- 4.4.7. Para-Hypothalamic Tumours with Mechanical Changes, Displacement and Chronic Damage.- 4.4.7 a. Pre-Operative.- 4.4.7 b. First Post-Operative Day.- 4.4.8. Patients with Hemisphere Tumours Close to the Cortex.- 4.4.8 a. Pre-Operative.- 4.4.8 b. First Post-Operative Day.- 4.4.8 c. Seventh Post-Operative Day.- 4.4.9. Unconscious Patients with Acute “Midbrain Syndrome”.- 4.4.10. Unconscious Patients with Acute Mesencephalo-Ponto-Bulbar Lesions.- 4.4.11. Unconscious Patients, Regardless of the Site and Level of the Lesion, or the Cerebral Cause.- 4.4.12. Unconscious Patients with the Clinical Signs of Brain Death.- 4.4.13. Patients with Complete Lesions of the Upper Cervical Cord.- 4.5. Mean Hourly Concentrations in the Various Groups, in Response to a Glucose Load.- 4.5.1. Glucose.- 4.5.2. Insulin.- 4.5.3. Human Growth Hormone.- 4.5.4. Cortisol.- 4.5.5. Glucagon.- 4.5.6. Mean Concentrations of the Catecholamines in 24 Hour Urine.- 4.6. The Molar Insulin-Glucagon Quotient in the Various Groups.- 4.7. Pharmacokinetic Investigation of the Concentration Pattern and of the Assimilation of the Blood Glucose After an Intravenous Glucose Load.- 4.7.1. Glucose Assimilation.- 4.7.2. Glucose Transfer.- 4.8. Inhibition Tests with Somatostatin.- 5. Consideration of the Results and Discussion.- 6. Summary.- References.